Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study

(2021) Matthias Hepprich et al.   Diabetes Therapy

Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE C anada multicentre, prospective, observational study

(2021) Jean‐François Yale et al.   DIABETES OBESITY & METABOLISM

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study

(2021) Gottfried Rudofsky et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study

(2021) Neda Rajamand Ekberg et al.   Primary Care Diabetes

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

(2021) Patrick Holmes et al.   Diabetes Therapy

Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs

(2020) Angelica Artasensi et al.   MOLECULES

954-P: GLP-1–Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study)

(2020) ILDIKO LINGVAY et al.   DIABETES

Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry ( SPARE study)

(2020) Ruth E Brown et al.   DIABETES OBESITY & METABOLISM

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study

(2020) Akshay B. Jain et al.   Diabetes Therapy

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

(2019) Bernard Zinman et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

(2019) M.S. Capehorn et al.   DIABETES & METABOLISM

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

(2019) Ildiko Lingvay et al.   Lancet Diabetes & Endocrinology

Efficacy of semaglutide versus liraglutide in clinical practice

(2019) E. Goncalves et al.   DIABETES & METABOLISM

6. Glycemic Targets: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

(2018) Helena W Rodbard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

(2018) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

(2018) Lawrence Blonde et al.   ADVANCES IN THERAPY

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

Guidelines for good pharmacoepidemiology practice (GPP)

(2015)   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION